Price Don’t Lie: After Today’s Significant Decline, Is Aegerion Pharmaceuticals, Inc.’s Near-Term Analysis Negative?

Price Don't Lie: After Today's Significant Decline, Is Aegerion Pharmaceuticals, Inc.'s Near Term Analysis Negative?

The stock of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is a huge mover today! About 158,352 shares traded hands. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has declined 55.02% since March 9, 2016 and is downtrending. It has underperformed by 62.43% the S&P500.
The move comes after 7 months negative chart setup for the $66.99 million company. It was reported on Oct, 12 by Barchart.com. We have $2.08 PT which if reached, will make NASDAQ:AEGR worth $8.04M less.

Analysts await Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) to report earnings on November, 14.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Ratings Coverage

Out of 5 analysts covering Aegerion Pharmaceuticals (NASDAQ:AEGR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Aegerion Pharmaceuticals has been the topic of 9 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was upgraded by Bank of America to “Neutral” on Wednesday, November 11. The rating was upgraded by Jefferies on Tuesday, July 28 to “Buy”. The stock has “Buy” rating given by Guggenheim on Monday, December 21. The stock has “Hold” rating given by Zacks on Friday, August 7. The company was downgraded on Friday, February 12 by Bank of America.

According to Zacks Investment Research, “Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.”

More news for Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) were recently published by: Bostonglobe.com, which released: “Aegerion Pharmaceuticals to merge with Canadian drug maker” on June 15, 2016. Rttnews.com‘s article titled: “Aegerion Pharmaceuticals Inc. (AEGR) Is Up After Japanese Approval For JUXTAPID” and published on September 28, 2016 is yet another important article.

AEGR Company Profile

Aegerion Pharmaceuticals, Inc., incorporated on February 4, 2005, is a biopharmaceutical company. The Firm is engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Firm operates through pharmaceuticals segment. The Company’s products include lomitapide and metreleptin.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment